Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The osteosarcoma marketed and pipeline drugs assessment report provides a data-driven overview of the current and future competitive landscape in osteosarcoma therapeutics. Osteosarcoma is the most common primary pediatric bone malignancy, derived from primitive bone-forming mesenchymal cells, and is characterized by extensive and heterogeneous genetic complexity.

Osteosarcoma can be classified into various subtypes according to the degree of differentiation, location within the bone, and histological variation. Osteosarcoma can also be subdivided into primary and secondary forms. Primary tumors usually occur in the metaphysis of long bones around the knee. Children and adolescents account for the vast majority of those affected by this condition. Secondary tumors occur in higher incidence in flat bones such as the pelvis. It has a wider distribution due to the varied nature of the patients’ underlying predisposing conditions. Secondary tumors almost always occur in the adult population.

Osteosarcomas frequently occur near the metaphysis of the long bones of the appendicular skeleton. The most common locations include the femur, the tibia, and the humerus. Other potential sites include the skull or jaw and the pelvis. The prognosis of osteosarcoma depends on various factors such as age, gender, biomarker levels, tumor location, tumor burden, pathological fracture, and body mass index, among others.

What are the key regions in the osteosarcoma drugs market?

The key regions in the osteosarcoma drugs market are the US, Europe, and Asia-Pacific. The US has the highest number of trials in phase II, followed by Asia-Pacific and then Europe.

Which are the major countries in the osteosarcoma drugs market?

The major countries in the osteosarcoma drugs market are France, the US, China, Canada, the UK, Netherlands, Australia, Denmark, Belgium, and New Zealand. The US has the highest number of completed trials among the other top countries.

Osteosarcoma drugs market, by major countries

Osteosarcoma drugs market, by major countries

For more country insights, download a free sample

Which are the key drugs in the osteosarcoma drugs market?

The key drugs in the osteosarcoma drugs market include doxorubicin hydrochloride, ifosfamide, cisplatin, leucovorin calcium, levoleucovorin calcium, methotrexate, mifamurtide, and vincristine sulfate.

Osteosarcoma drugs market, by key drugs

Osteosarcoma drugs market, by key drugs

For more drug insights, download a free sample

What are the key phases in the osteosarcoma drugs market?

The key phases in the osteosarcoma drugs market include discovery, pre-clinical, IND/CTA filed, phase I, phase II, and phase III. Among them phase II contains majority of the pipeline.

Osteosarcoma drugs market, by key phases

Osteosarcoma drugs market, by key phases

For more phase insights, download a free sample

Who are the key sponsors in the osteosarcoma drugs market?

The key sponsors in the osteosarcoma drugs market include Novartis, Celgene, Cellectar Biosciences, Eisai, and Isofol Medical. Novartis is the top sponsor in osteosarcoma clinical research with four clinical trials. After Novartis, the most active sponsors of osteosarcoma clinical trials are Celgene, Cellectar Biosciences, Eisai, and Isofol Medical.

Osteosarcoma drugs market, by key sponsors

Osteosarcoma drugs market, by key sponsors

To know about more key sponsors, download a free sample

Market report scope

Key regions The US, Europe, and Asia-Pacific
Major countries France, the US, China, Canada, the UK, Netherlands, Australia, Denmark, Belgium, and New Zealand
Key phases Discovery, Pre-Clinical, IND/CTA Filed, Phase I, Phase II, and Phase III
Key drugs Doxorubicin Hydrochloride, Ifosfamide, Cisplatin, Leucovorin Calcium, Levoleucovorin Calcium, Methotrexate, Mifamurtide, and Vincristine Sulfate
Key sponsors Novartis, Celgene, Cellectar Biosciences, Eisai, and Isofol Medical

Scope

  • GlobalData’s Osteosarcoma marketed and pipeline drugs assessment, clinical trials, social media and competitive landscape, 2021-2027 combines data from the pharma intelligence center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the osteosarcoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global osteosarcoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview Epidemiology Overview

3.3 Epidemiology

4 Marketed Drugs Assessment

4.1 Marketed Drugs Overview

5 Pipeline Assessment

5.1 Pipeline Overview

5.2 Pipeline Breakdown by Region

5.3 Pipeline Breakdown by Molecule Type and Target

5.4 Drug Review Designations

5.5 Phase Transition Success Rates

5.6 Likelihood of Approval

6 Clinical Trial Assessment

6.1 Clinical Trials Overview by Phase

6.2 Overview by Region

6.4 Therapy Area Perspective

6.4 Leading Sponsors

6.5 Enrollment Analytics

6.6 Feasibility Analysis

7 Commercial Assessment

7.1 Upcoming Market Catalysts

8 Appendix

8.1 Methodology

8.2 About the Authors

8.3 About GlobalData

8.4 Contact Us

8.5 Disclaimer

Frequently asked questions

Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape thematic reports
Currency USD
$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.